| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $167,617,727 | 74 | 100 |
| Bonstein Sara | Chief Financial Officer | 0 | $0 | 6 | $2.13M | $-2.13M |
| ANDERSON ELIZABETH M | director | 0 | $0 | 2 | $2.98M | $-2.98M |
| Brennan David R | director | 0 | $0 | 1 | $3.1M | $-3.1M |
| SHAROKY MELVIN MD | director | 0 | $0 | 2 | $4.74M | $-4.74M |
| Smith Michael Alexander | Chief Legal Officer | 0 | $0 | 11 | $14M | $-14M |
| LEE LEO | director | 0 | $0 | 1 | $14.69M | $-14.69M |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer | 0 | $0 | 2 | $21.11M | $-21.11M |
| Flammer Martina M.D. | Chief Medical Officer | 0 | $0 | 18 | $26.67M | $-26.67M |
| Lewis William | Chair and CEO | 0 | $0 | 24 | $34.93M | $-34.93M |
| Adsett Roger | Chief Operating Officer | 0 | $0 | 8 | $48.25M | $-48.25M |
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its …
Over the last 12 months, insiders at Insmed Incorporated have bought $0 and sold $167.62M worth of Insmed Incorporated stock.
On average, over the past 5 years, insiders at Insmed Incorporated have bought $751,715 and sold $84.56M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,130 shares for transaction amount of $74,976 was made by Desjardins Clarissa (director) on 2025‑05‑21.
| 2026-09-09 | Sale | Brennan David R | director | 25,000 0.0111% | $124.00 | $3.1M | -15.69% | |
| 2026-08-17 | Sale | SHAROKY MELVIN MD | director | 5,000 0.0023% | $127.53 | $637,650 | -8.17% | |
| 2026-08-10 | Sale | Adsett Roger | Chief Operating Officer | 239,850 0.1091% | $133.27 | $31.96M | -11.52% | |
| 2026-08-06 | Sale | Flammer Martina M.D. | Chief Medical Officer | 27,173 0.0122% | $128.61 | $3.49M | -9.50% | |
| 2026-07-23 | Sale | Lewis William | Chair and CEO | 10,700 0.0049% | $106.06 | $1.13M | +9.63% | |
| 2026-07-09 | Sale | Lewis William | Chair and CEO | 10,699 0.0049% | $117.40 | $1.26M | -5.22% | |
| 2026-07-06 | Sale | Flammer Martina M.D. | Chief Medical Officer | 12,302 0.0056% | $109.98 | $1.35M | +1.17% | |
| 2026-06-25 | Sale | Lewis William | Chair and CEO | 17,650 0.008% | $102.83 | $1.81M | +6.82% | |
| 2026-06-25 | Sale | Lewis William | Chair and CEO | 21,398 0.0098% | $103.32 | $2.21M | +6.82% | |
| 2026-06-22 | Sale | Smith Michael Alexander | Chief Legal Officer | 1,806 0.0008% | $95.82 | $173,051 | +12.90% | |
| 2026-06-08 | Sale | Lewis William | Chair and CEO | 6,515 0.003% | $94.03 | $612,605 | +15.90% | |
| 2026-06-05 | Sale | Flammer Martina M.D. | Chief Medical Officer | 1,858 0.0008% | $103.78 | $192,823 | +15.56% | |
| 2026-06-03 | Sale | Lewis William | Chair and CEO | 7,605 0.0035% | $102.27 | $777,763 | +4.57% | |
| 2026-06-03 | Sale | Adsett Roger | Chief Operating Officer | 2,370 0.0011% | $102.27 | $242,380 | +4.57% | |
| 2026-06-03 | Sale | Bonstein Sara | Chief Financial Officer | 2,404 0.0011% | $102.27 | $245,857 | +4.57% | |
| 2026-06-03 | Sale | Flammer Martina M.D. | Chief Medical Officer | 2,566 0.0012% | $102.27 | $262,425 | +4.57% | |
| 2026-06-03 | Sale | Smith Michael Alexander | Chief Legal Officer | 2,159 0.001% | $102.27 | $220,801 | +4.57% | |
| 2026-05-22 | Sale | Smith Michael Alexander | Chief Legal Officer | 6,149 0.0028% | $108.47 | $666,982 | +1.96% | |
| 2026-05-18 | Sale | Lewis William | Chair and CEO | 25,564 0.0117% | $106.33 | $2.72M | +0.71% | |
| 2026-05-14 | Sale | Flammer Martina M.D. | Chief Medical Officer | 10,479 0.0049% | $117.54 | $1.23M | -6.67% |
| Lewis William | Chair and CEO | 259058 0.1181% | $27.06M | 7 | 75 | +45.59% |
| Adsett Roger | Chief Operating Officer | 98744 0.045% | $10.31M | 1 | 37 | +43.16% |
| LEE LEO | director | 54677 0.0249% | $5.71M | 1 | 1 | +15.36% |
| Brennan David R | director | 39238 0.0179% | $4.1M | 1 | 1 | <0.0001% |
| SHAROKY MELVIN MD | director | 0 0% | $0 | 13 | 12 | +30.83% |
| ALLAN GEOFFREY | President, CEO and Chairman | 1166464 0.5317% | $121.83M | 1 | 0 | +1.39% |
| ENGELSEN STEINAR J | director | 320802 0.1462% | $33.5M | 9 | 0 | +12.65% |
| TULLY KEVIN P | Executive VP & CFO | 142252 0.0648% | $14.86M | 1 | 0 | <0.0001% |
| Pellizzari Christine A | Chief Legal Officer | 140721 0.0641% | $14.7M | 4 | 8 | |
| Glover Steve C | President Follow-on Biologics | 80000 0.0365% | $8.36M | 1 | 0 | <0.0001% |
| Farrar Doug | Vice President, ITP | 74813 0.0341% | $7.81M | 4 | 0 | <0.0001% |
| HAYDEN DONALD J JR | director | 62197 0.0284% | $6.5M | 3 | 8 | <0.0001% |
| CROOKE GRAHAM K | director | 60000 0.0273% | $6.27M | 3 | 0 | <0.0001% |
| WHITCOMB RANDALL W | director | 29840 0.0136% | $3.12M | 2 | 1 | <0.0001% |
| Whitten Timothy | President & CEO | 10000 0.0046% | $1.04M | 2 | 0 | +43.09% |
| Desjardins Clarissa | director | 3025 0.0014% | $315,931.00 | 2 | 0 | +116.81% |
| GUPTA RENU | EVP & Chief Medical Officer | 2000 0.0009% | $208,880.00 | 2 | 0 | <0.0001% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
Insmed Incorporated (INSM) | $11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 440 | +72.97% | 30M | +14.06% |
| Decreased Positions | 274 | -45.44% | 30M | -13.95% |
| New Positions | 194 | New | 6M | New |
| Sold Out Positions | 82 | Sold Out | 7M | Sold Out |
| Total Postitions | 769 | +27.53% | 214M | +0.11% |
| Jpmorgan Chase & Co | $4.08M | 10.82% | 23.05M | +7M | +47.4% | 2025-09-30 |
| Darwin Global Management, Ltd. | $3.62M | 9.6% | 20.46M | +1M | +5.75% | 2025-09-30 |
| Vanguard Group Inc | $3.53M | 9.36% | 19.94M | +2M | +12.99% | 2025-09-30 |
| Blackrock, Inc. | $2.19M | 5.81% | 12.36M | +1M | +10.97% | 2025-09-30 |
| Fmr Llc | $1.63M | 4.31% | 9.18M | +4M | +80.26% | 2025-09-30 |
| Capital International Investors | $1.34M | 3.55% | 7.55M | +74,994 | +1% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $1.23M | 3.25% | 6.93M | -4M | -38.28% | 2025-09-30 |
| Baker Bros. Advisors Lp | $1.19M | 3.15% | 6.7M | -1M | -13.09% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $1M | 2.66% | 5.66M | +2M | +65.3% | 2025-09-30 |
| Artisan Partners Limited Partnership | $874,562.00 | 2.32% | 4.94M | +2M | +48.98% | 2025-09-30 |